[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dietary-supplement\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dietary-supplement":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,78,103,131],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100549384","phase-4-understanding-the-efficacy-of-dietary-supplement-on-fungal-mycobiota-in-healthy-volunteers-a-pilot-study-100549384",false,"NCT06433310","Understanding the Efficacy of Dietary Supplement on Fungal Mycobiota in Healthy Volunteers: A Pilot Study","Inclusion Criteria:\n\n* Male or female adults over the age of 18 years\n\nExclusion Criteria:\n\n* History of a diagnosis of any gastrointestinal condition, such as inflammatory bowel syndrome or disease\n* Antibiotic usage within the past two weeks\n* Antifungal usage within the past month\n* Allergy to L-Phenylalanine or individuals with phenylketonuria (PKU)\n* Adults taking medications known to interact with L-phenylalanine supplements, such as Monoamine Oxidase Inhibitors (MOAI), L-DOPA, and some antipsychotic drugs (complete and extensive drug list will be provided to interested participants during screening)\n* Pregnant or nursing women",true,"ALL","18 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","The purpose of this study is to explore how the dietary supplement L-Phenylalanine affects the production of the metabolite phenylpropionic acid (PPA) and changes fungal populations of the gut microbiome.",[26,27,28,29,30],"Gut Microbiome","Gut Health","Dietary Supplement","L-Phenylalanine","Phenylpropionic Acid","RECRUITING","2026-06-23",{"date":34,"type":35},"2026-06-26","ACTUAL",{"date":37,"type":35},"2024-10-17",{"date":39,"type":20},"2027-12-31",{"name":41,"class":42},"Weill Medical College of Cornell University","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":15,"sex":51,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":58,"conditions":59,"keywords":63,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":43},"100633635","evaluation-of-oral-collagen-peptides-on-skin-barrier-function-in-women-100633635","NCT07529249","Evaluation of Oral Collagen Peptides on Skin Barrier Function in Women","Evaluation of Oral Collagen Peptides on Skin Barrier Function in Women With Dry Skin","Inclusion Criteria:\n\n1. Participant having signed an Informed Consent Form (ICF);\n2. Healthy female Participant aged 45 to 70 years inclusive not followed by a healthcare practitioner for any skin disease;\n3. Participant with phototype II to IV according to the Fitzpatrick classification;\n4. Participant with dry skin measured on the cheeks (Tewameter, TEWL \\>15g\u002Fm²\u002Fh (skin barrier integrity) on back of the cheekbone)\n5. Female Participant of non-childbearing potential, defined as a woman without uterus and\u002For both ovaries, surgically sterile (at least 6 months prior to Screening visit) or post-menopausal (at least one year post cessation of menses);\n6. Female Participant of childbearing potential who has been using a highly effective birth control method for at least 1 month prior to Screening visit and agreeing to continue adequate contraception during the entire study period;\n\n   Highly effective birth control methods are:\n\n   \\- hormonal (combined or progestogen-only) contraception methods associated with inhibition of ovulation or intrauterine device; bilateral tubal occlusion since at least 3 months prior to Screening visit; vasectomised partner; True abstinence, i.e., refraining from heterosexual intercourse when this is in line with the preferred and usual lifestyle of the participant.\n7. Participant agreeing not to apply any cosmetic product (e.g. care cream, lotion, body milk) or drug on the face (except usual cleansing products) within 24 hours before the study visits;\n8. Participant agreeing to not apply cosmetic, medical, or aesthetic treatments out of the study protocol on the face and legs during the whole study duration;\n9. Participant affiliated to a health social security system (according to French Law).\n\nExclusion Criteria:\n\n1. Participant with a BMI ≤17 or ≥30 kg\u002Fcm²;\n2. Participant with any uncontrolled diseases such as diabetes, hypertension, hyperthyroidism or hypothyroidism;\n3. Presenting or having a history of eating disorder (e.g. anorexia, food allergy) or gastrointestinal malabsorption such as celiac disease, Crohn's disease, lactose intolerance;\n4. Participant with an history of sleeve or bypass;\n5. Participant currently participating in another clinical study or being in an exclusion period of another clinical study;\n6. Participant with known or suspected hypersensitivity to any component(s) of the investigational products or to any ingredients of the vehicles (i.e., excipients);\n7. Participant with a known allergy to beef-derived products;\n8. Participant who has used collagen supplements, vitamin C, or other skin related nutraceuticals within the last 3 months\n9. Participant who started using prescription medications to treat skin conditions or other medications that affect the skin during the three months prior to the study\n10. Participant who has made significant lifestyle changes in the past three months (altering their diet, starting new exercises, or changing their skincare routines)\n11. Participant with skin abnormalities (e.g., scars, excessive hair, tattooing) or any dermatosis (e.g., psoriasis, eczema, acne vulgaris) on the face and legs which could interfere with the study;\n12. Participant impossible to contact in case of emergency;\n13. Participant who, in the opinion of the investigator, is unlikely to comply with the Clinical Study Protocol (e.g., alcoholism, drug dependency or psychotic state);\n14. Participant who is in an exclusion period in the National Biomedical Research Register of the French Ministry of Health at randomization;\n15. Protected participant as defined in the Articles of the French Public Health Code. Article 1121-7: person deprived of liberty by a judicial or administrative decision, or participant to psychiatric care, or person admitted to a health or social institution for purposes other than the research. Article 1121-8: adult person participant to a legal protection measure or unable to express his\u002Fher consent. Article L3212-1: person undergoing compulsory psychiatric treatment. Article L3213-1: person having a mental disorder that requires care and that which may compromise the safety of third persons or seriously undermine public order;\n16. Participant unable to communicate or cooperate with the Investigator;\n17. Participant having received 6000 euros indemnities for participation in clinical trials\u002Finvestigations in the 12 previous months, including participation in the present study (according to French Law);","FEMALE","45 Years","70 Years",{"count":55,"type":20},75,[57],"NA","This clinical study aims to determine whether taking two different doses of collagen-derived peptides for three months improves facial skin barrier integrity in women with dry, sensitive skin, compared with a placebo.",[60,61,62,28],"Dry Skin","Sensitive Skin","Dry Skin in the Elderly",[64,65,66,67,68],"cpcad","skinpharma","dry skin","dietary supplement","sensitive skin","2026-05-07",{"date":71,"type":35},"2026-05-12",{"date":73,"type":20},"2026-04",{"date":75,"type":20},"2026-09",{"name":77,"class":42},"Centre de Pharmacologie Clinique Applique a la Dermatologie",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":82,"acronym":83,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":16,"minAge":85,"maxAge":17,"enrollmentInfo":86,"targetDuration":4,"studyType":21,"phases":88,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":43},"100586502","study-of-the-effect-of-capsinoid-supplementation-on-brown-adipose-tissue-in-obese-adolescents-100586502","NCT06916208","Study of the Effect of Capsinoid Supplementation on Brown Adipose Tissue in Obese Adolescents","ADOBAT","Inclusion Criteria:\n\n* member or beneficiary of a health insurance scheme\n* aged between 11 and 18\n* Body Mass Index Z score corresponding to stage 2 obesity according to the curves of Rolland-Cachera et al., 1991 and an absence of weight loss of more than 5% of the total weight over the last 3 months.\n* effective contraception (in pubescent females)\n\nExclusion Criteria:\n\n* known allergy to capsinoids and\u002For soya\n* inflammatory digestive pathology and\u002For history of digestive tract surgery\n* participation in another study or in a period of exclusion determined by a previous study\n* pregnant, parturient or breastfeeding\n* The holder(s) of parental authority or the adolescent refuse(s) to sign the authorisation or acceptance form, respectively.\n* It proves impossible to provide the adolescent or parental guardian(s) with informed information.","11 Years",{"count":87,"type":20},38,[57],"Among the new strategies being considered for the treatment of obesity and its metabolic complications, the activation of brown adipose tissue (BAT) from white adipose tissue looks promising. Interest in the study of BAT has increased over the last 5-10 years in response to the discovery of functional BAT in humans. The BAT is a tissue specialized in regulating energy expenditure by producing heat through the oxidation of fatty acids contained in the multiple lipid droplets of brown adipocytes. This adipose tissue does not play a storage role, but rather an anti-obesogenic one, thanks to its high metabolic and energetic activity.\n\nIn addition to exposure to cold, which is the major physiological inducer of brown adipocytes, it seems that exercise and the intake of \"adrenergic\" foods can activate the TAB and potentially induce a change from white to brown tissue via the production of adrenalin and myokines. Acute and\u002For chronic effects of thermogenic food supplements have been reported on BAT activation and energy metabolism. The most conclusive of these involve the capsinoids found in sweet peppers and chillies. Weight loss also improves BAT activation.\n\nThe BAT has already been identified in children. A decrease in its volume and activity from childhood to adolescence and during puberty has been reported.\n\nThe main objective of this randomized controlled double-blind study is to investigate the effects of capsinoid dietary supplementation on BAT activity in obese adolescents.\n\nOur general working hypothesis is that capsinoid supplementation, combined with dietary management, leads to an increase in BAT activity.",[91,92,93,28],"Obese Adolescents","Exercise","Diet Modification","2026-04-29",{"date":96,"type":35},"2026-04-30",{"date":98,"type":35},"2025-03-03",{"date":100,"type":20},"2027-03",{"name":102,"class":42},"University of Avignon",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":110,"enrollmentInfo":111,"targetDuration":4,"studyType":21,"phases":113,"briefSummary":114,"conditions":115,"keywords":117,"overallStatus":121,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":4},"100602767","non-inferiority-rct-on-fish-waste-derived-vs-synthetic-vitamin-d-supplementation-in-healthy-adults-with-suboptimal-vitamin-d-levels-100602767","NCT07127796","Non-inferiority RCT on Fish Waste-Derived vs. Synthetic Vitamin D Supplementation in Healthy Adults With Suboptimal Vitamin D Levels","A Non-inferiority, Randomized Double-blind Controlled Clinical Trial Comparing the Effect of Vitamin D Supplementation Derived From Fish Waste Versus Synthetic Vitamin D on Plasma Vitamin D Levels and Anthropometric and Laboratory Correlates in Healthy Subjects With Suboptimal Blood Vitamin D Levels","Inclusion Criteria:\n\n* Male or female aged ≥ 18 years and ≤ 60 years old\n* Vitamin D plasma level between 20 and 40 ng\u002FmL\n* Subjects who have the capability to communicate, to make themselves understood, and to comply with the study's requirements\n* Subjects agree to participate in the study and having dated and signed the informed consent form\n\nExclusion Criteria:\n\n* Intake of dietary supplements or drugs containing Vitamin D\n* Diagnosis of osteopenia\u002Fosteoporosis, rheumatological diseases, history of non-traumatic bone fractures\n* Known diagnosis of hyperparathyroidism, hypercalcemia, severe renal failure (eGFR\\\u003C30 mg\u002FdL) Known intolerance or allergy to fish or fish derived products\n* Any preventive treatments (i.e. hypocholesterolemics, antihypertensives) not stabilized in type and dose for at least 3 months\n* Active pregnancy or lactation\n* Any medical or surgical condition that would limit the patient adhesion to the study protocol","60 Years",{"count":112,"type":20},48,[57],"Vitamin D is a fat-soluble vitamin with hormone-like properties, essential for numerous physiological processes in humans. It plays a central role in maintaining calcium and phosphorus homeostasis, promoting intestinal absorption of these minerals, and ensuring optimal bone mineralization. There are two main forms: vitamin D2 (ergocalciferol), primarily obtained from plant sources and supplements, and vitamin D3 (cholecalciferol), synthesized endogenously in the skin through exposure to ultraviolet B (UVB) radiation and present in animal-derived foods such as fatty fish, liver, and egg yolks. Beyond its well-known skeletal functions, vitamin D contributes to muscle contraction, immune system modulation, and regulation of cell proliferation and differentiation. Increasing evidence suggests that adequate vitamin D status may benefit cardiovascular health, glucose metabolism, and possibly reduce the risk of certain cancers, while supplementation has been associated with improved plasma lipid profiles, a relevant factor in cardiovascular risk reduction. The European Food Safety Authority has authorized various health claims for vitamin D, including its role in normal calcium and phosphorus absorption and utilization, maintenance of normal blood calcium concentrations, bone and teeth health, normal muscle function, immune defense, and reduction of the risk of falls in older adults. Despite its importance, vitamin D deficiency is recognized as a widespread public health concern across Europe, with prevalence influenced by latitude, season, skin pigmentation, and lifestyle habits. Data indicate that up to 40% of Europeans have suboptimal vitamin D levels, with deficiency rates exceeding 70% in specific high-risk groups such as elderly individuals, people with dark skin, and those with limited sun exposure. In Italy, despite abundant sunlight, vitamin D insufficiency is highly prevalent, particularly in older adults and patients with chronic illnesses. Contributing factors include urbanization, sedentary lifestyles, reduced time spent outdoors, and cultural or clothing practices limiting sun exposure. Approximately half of the Italian population is estimated to have insufficient vitamin D levels, with rates rising in the northern regions during winter months. Prolonged deficiency has severe consequences for skeletal health, including rickets in children, osteomalacia in adults, and increased risk of osteoporosis and fractures. It is also linked to a broad range of extra-skeletal effects, such as impaired immune response with greater susceptibility to infections, increased risk of chronic diseases including cardiovascular disorders, type 2 diabetes, and certain cancers, as well as muscle weakness, higher likelihood of falls, and mood disorders such as depression and seasonal affective disorder. Addressing vitamin D deficiency requires a multifaceted approach involving dietary supplementation, food fortification strategies, and public health initiatives promoting safe sunlight exposure. Severe deficiency requires pharmacological treatment with appropriately dosed medications, whereas mild deficiency can be corrected through over-the-counter supplements. In Italy, vitamin D supplements contain up to 2000 IU per day, with the recommended daily allowance for healthy adults set at 600 IU. The demand for vitamin D supplementation is reflected in market trends: the global market was valued at USD 1.69 billion in 2022 and is projected to reach USD 3.44 billion by 2031, with an estimated compound annual growth rate of 8.22% between 2023 and 2031. Against this background, the exploration of natural, sustainable sources of vitamin D, particularly from food industry by-products such as fish waste, offers an environmentally friendly alternative to synthetic forms currently dominating the market. This concept underpins the PRIN research project \"Innovative and sustainable processes for the development of Vitamin D nutraceutical from fish waste: extraction, formulation and clinical study for the evaluation of its bioavailability and clinical consequence\" (VITADWASTE; 2022M9JL3%; National Coordinator: Prof. Gianni Sagratini, University of Camerino), supported by the Italian Ministry of University. The project aims to develop and clinically evaluate a fish-derived vitamin D nutraceutical as a sustainable solution. Within this context, the primary objective of the present randomized, double-blind, non-inferiority clinical trial is to assess whether supplementation with fish-derived vitamin D at a dose of 600 IU per day, corresponding to 100% of the recommended daily intake for healthy adults, has an effect on plasma vitamin D levels comparable to that of an equivalent dose of standard synthetic vitamin D in healthy adults with mild vitamin D deficiency, defined by plasma concentrations between 20 and 40 ng\u002FmL.",[116,28],"Vitamin D",[116,118,119,120],"Dietary supplement","Food waist","Fish-derived vitamin D","NOT_YET_RECRUITING","2026-04-27",{"date":124,"type":35},"2026-05-01",{"date":126,"type":20},"2026-09-01",{"date":128,"type":20},"2027-09-10",{"name":130,"class":42},"University of Bologna",{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":21,"phases":141,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":43},"100609605","effects-of-breathing-training-and-nitrate-on-exercise-at-simulated-altitude-100609605","NCT07216755","Effects of Breathing Training and Nitrate on Exercise at Simulated Altitude","Impact of Respiratory Muscle Training and Nitrate Therapy on Exercise Tolerance in Simulated Altitude","Inclusion Criteria:\n\n* Healthy adults between 18 and 40 years old.\n\nRecreationally active (performing ≥3 hours of structured physical activity per week).\n\nNon-smokers for at least the past 6 months.\n\nFree from any known cardiovascular, pulmonary, metabolic, or neuromuscular disease as determined by health screening questionnaire and medical history.\n\nAble to perform cycle ergometer exercise to volitional fatigue.\n\nWilling to abstain from high-nitrate foods and supplements (e.g., beets, spinach, arugula) for 48 hours prior to each testing session.\n\nAble and willing to provide written informed consent and comply with all study procedures.\n\nExclusion Criteria:\n\n* Diagnosis of or history of heart disease, hypertension, diabetes, or chronic respiratory disorders (e.g., asthma, COPD).\n\nCurrent use of medications or supplements known to affect cardiovascular, metabolic, or respiratory function (e.g., beta-blockers, nitrates, stimulants).\n\nSmoking, vaping, or tobacco use within the past 6 months.\n\nKnown allergy or intolerance to beetroot products or nitrates.\n\nParticipation in another interventional research study within the past 30 days.\n\nPregnant or breastfeeding women.\n\nAny orthopedic or musculoskeletal limitation preventing safe exercise testing.\n\nFailure to meet inclusion criteria or inability to complete familiarization and baseline testing.","40 Years",{"count":140,"type":20},80,[57],"This study investigates whether respiratory muscle training (RMT) and dietary nitrate supplementation can improve exercise tolerance under simulated moderate altitude conditions. Exposure to reduced oxygen availability at altitude places additional strain on the cardiovascular and respiratory systems, which may limit endurance performance. By combining RMT-designed to strengthen the muscles involved in breathing-with nitrate therapy, which enhances nitric oxide availability and vascular function, this study aims to determine whether these interventions independently or synergistically improve oxygen delivery, reduce physiological strain, and enhance exercise performance. The findings will help identify non-pharmacological strategies to improve physical performance and tolerance to hypoxia in both clinical and operational environments.",[144,145,146,147,148,28,149,150],"Healthy Adults","Mechanical Ventilation Dependence","Hypoxia","Exercise Training","Exercise Intolerance","Nitrate Supplementation","Inspiratory Muscle Training","2025-10-13",{"date":153,"type":35},"2025-10-15",{"date":155,"type":35},"2025-09-01",{"date":157,"type":20},"2028-08-31",{"name":159,"class":42},"Embry-Riddle Aeronautical University"]